Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-10-20

Clinical Trial Update: Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream [Phase 2]

View source ↗

Summary

Phase 2 trial exploring genomic markers before and after treatment of actinic keratosis with imiquimod 3.75% cream.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imiquimod 3.75% Cream (Imiquimod)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Actinic Keratosis | Phase 2 | Status: COMPLETED | Results posted: 2020-10-20